Grants per year
Personal profile
Training Experience
| 2003 | Residency, Royal College of Physicians, Ireland |
| 2009 | Fellowship, University of Texas Health Science Center, San Antonio |
| 2009 | Fellowship, Royal College of Physicians, Ireland |
Education/Academic qualification
PhD, National University of Ireland
… → 2009
MBBChBAO, National University of Ireland
… → 2000
Fingerprint
Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #ADCT-901-101: A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors
Clinipace, Inc., ADC Therapeutics Sarl
4/27/22 → 4/27/25
Project: Research project
-
Prot #DT2216-001: A Phase 1, Open-Label, Dose Escalation, And Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics (PK) And Clinical Activity Of DT2216, An Antiapoptotic Protein Targeted Degradation Compound, In Subjects With Rela
SCRI Development Innovations, LLC, Dialectic Therapeutics, Inc.
1/5/22 → 1/5/25
Project: Research project
-
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01
Sahai, V., Griffith, K. A., Beg, M. S., Shaib, W. L., Mahalingam, D., Zhen, D. B., Deming, D. A. & Zalupski, M. M., Oct 1 2022, In: Cancer. 128, 19, p. 3523-3530 8 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
Arora, S. P., Tenner, L., Sarantopoulos, J., Morris, J., Liu, Q., Mendez, J. A., Curiel, T., Michalek, J. & Mahalingam, D., 2022, (Accepted/In press) In: British Journal of Cancer.Research output: Contribution to journal › Article › peer-review
-
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
Zhou, X., Vaishampayan, U., Mahalingam, D., Harvey, R. D., Chung, K. Y., Sedarati, F., Dong, C., Faller, D. V., Venkatakrishnan, K. & Gupta, N., Oct 2022, In: Investigational New Drugs. 40, 5, p. 1042-1050 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort
Gupta, A. N., Gordon, A. C., Gabr, A., Kalyan, A., Kircher, S. M., Mahalingam, D., Mulcahy, M. F., Merkow, R. P., Yang, A. D., Bentrem, D. J., Caicedo-Ramirez, J. C., Riaz, A., Thornburg, B., Desai, K., Sato, K. T., Hohlastos, E. S., Kulik, L., Benson, A. B., Salem, R. & Lewandowski, R. J., Aug 2022, In: Cardiovascular and Interventional Radiology. 45, 8, p. 1117-1128 12 p.Research output: Contribution to journal › Article › peer-review
-
Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer
Osmulski, P. A., Cunsolo, A., Chen, M., Qian, Y., Lin, C. L., Hung, C. N., Mahalingam, D., Kirma, N. B., Chen, C. L., Taverna, J. A., Liss, M. A., Thompson, I. M., Huang, T. H. M. & Gaczynska, M. E., Aug 1 2021, In: Cancer Research. 81, 15, p. 4110-4123 14 p.Research output: Contribution to journal › Article › peer-review
6 Scopus citations